5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.36▼ | 1.35▼ | 1.35▼ | 1.47▼ | 1.58▼ |
MA10 | 1.36▼ | 1.35▲ | 1.40▼ | 1.71▼ | 3.18▼ |
MA20 | 1.35▼ | 1.40▼ | 1.42▼ | 1.66▼ | 4.54▼ |
MA50 | 1.37▼ | 1.48▼ | 1.67▼ | 3.52▼ | 6.38▼ |
MA100 | 1.40▼ | 1.71▼ | 1.70▼ | 4.78▼ | 7.10▼ |
MA200 | 1.54▼ | 1.65▼ | 2.28▼ | 6.30▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.003▲ | 0.005▲ | 0.006▲ | 0.080▲ | -0.381▼ |
RSI | 46.859▼ | 36.368▼ | 31.337▼ | 30.211▼ | 26.940▼ |
STOCH | 41.667 | 36.349 | 7.956▼ | 18.220▼ | 4.775▼ |
WILL %R | -80.000▼ | -90.476▼ | -90.476▼ | -98.851▼ | -99.552▼ |
CCI | 17.839 | 2.393 | -56.736 | -117.977▼ | -96.234 |
Wednesday, April 30, 2025 10:38 PM
2-Year U.S. Treasury Note Continuous Contract $104.117 0.043 0.04% 5-Year U.S. Treasury Note Continuous Contract $109.344 0.148 0.14% 10-Year U.S. Treasury Note Continuous Contract $112.438 0.219 ...
|
Friday, April 25, 2025 09:58 AM
Real time quote data is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.
|
Friday, April 25, 2025 05:13 AM
April 25, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 1.44 | 1.49 | 1.32 | 1.33 | 975,782 |
30/04/25 | 1.43 | 1.55 | 1.40 | 1.40 | 915,436 |
29/04/25 | 1.46 | 1.52 | 1.395 | 1.44 | 673,493 |
28/04/25 | 1.70 | 1.70 | 1.51 | 1.55 | 814,507 |
25/04/25 | 2.01 | 2.0836 | 1.61 | 1.64 | 16,140,757 |
24/04/25 | 2.00 | 2.00 | 1.86 | 1.99 | 204,174 |
23/04/25 | 2.09 | 2.12 | 1.9649 | 2.00 | 227,591 |
22/04/25 | 1.94 | 2.03 | 1.83 | 2.03 | 253,206 |
21/04/25 | 1.83 | 2.07 | 1.7606 | 1.91 | 314,582 |
17/04/25 | 1.85 | 1.87 | 1.66 | 1.81 | 236,493 |
|
|
||||
|
|
||||
|
|